Superselective Prostate Artery Embolization for Treatment of Severe Haematuria Secondary to Rapid Progression of Treatment-Induced Neuroendocrine Prostate Cancer: A Case Report

References

• Dai C, Heemers H, Sharifi N. Androgen signaling in prostate cancer. Cold Spring Harb Perspect Med. 2017;7:9. doi:10.1101/cshperspect.a030452
   Web of Science ®Google Scholar
• Long Z, Deng L, Li C, et al. Loss of EHF facilitates the development of treatment-induced neuroendocrine prostate cancer. Cell Death Dis. 2021;12(1):46. doi:10.1038/s41419-020-03326-8
   PubMed Web of Science ®Google Scholar
• Beltran H, Tagawa ST, Park K, et al. Challenges in recognizing treatment-related neuroendocrine prostate cancer. J Clin Oncol. 2012;30(36):e386–e389. doi:10.1200/JCO.2011.41.5166
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zheng D, Zhou T, et al. Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers. Nat Commun. 2018;9(1):4080. doi:10.1038/s41467-018-06177-2
   PubMed Web of Science ®Google Scholar
• Russo G, Mischi M, Scheepens W, De la Rosette JJ, Wijkstra H. Angiogenesis in prostate cancer: onset, progression and imaging. BJU Int. 2012;110(11c):E794–E808. doi:10.1111/j.1464-410X.2012.11444.x
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Huang J, Alumkal JJ, et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J Clin Oncol. 2018;36(24):2492–2503. doi:10.1200/JCO.2017.77.6880
   PubMed Web of Science ®Google Scholar
• Tan HL, Sood A, Rahimi HA, et al. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin Cancer Res. 2014;20(4):890–903. doi:10.1158/1078-0432.CCR-13-1982
   PubMed Web of Science ®Google Scholar
• Lee AR, Gan Y, Tang Y, Dong X. A novel mechanism of SRRM4 in promoting neuroendocrine prostate cancer development via a pluripotency gene network. EBioMedicine. 2018;35:167–177. doi:10.1016/j.ebiom.2018.08.011
   PubMed Web of Science ®Google Scholar
• Adams EJ, Karthaus WR, Hoover E, et al. FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature. 2019;571(7765):408–412. doi:10.1038/s41586-019-1318-9
   PubMed Web of Science ®Google Scholar
• Mohler JL, Antonarakis ES, Armstrong AJ, et al. Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(5):479–505. doi:10.6004/jnccn.2019.0023
   PubMed Web of Science ®Google Scholar
• Lovnicki J, Gan Y, Feng T, et al. LIN28B promotes the development of neuroendocrine prostate cancer. J Clin Invest. 2020;130(10):5338–5348. doi:10.1172/JCI135373
   PubMed Web of Science ®Google Scholar
• Wang HT, Yao YH, Li BG, et al. Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis. J Clin Oncol. 2014;32(30):3383–3390. doi:10.1200/JCO.2013.54.3553
   PubMed Web of Science ®Google Scholar
• Davies AH, Beltran H, Zoubeidi A. Cellular plasticity and the neuroendocrine phenotype in prostate cancer. Nat Rev Urol. 2018;15(5):271–286. doi:10.1038/nrurol.2018.22
   PubMed Web of Science ®Google Scholar
• Ge R, Wang Z, Montironi R, et al. Epigenetic modulations and lineage plasticity in advanced prostate cancer. Ann Oncol. 2020;31(4):470–479. doi:10.1016/j.annonc.2020.02.002
   PubMed Web of Science ®Google Scholar
• Lee JO, Russo AA, Pavletich NP. Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7. Nature. 1998;391(6670):859–865. doi:10.1038/36038
   PubMed Web of Science ®Google Scholar
• Ku SY, Rosario S, Wang Y, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science. 2017;355(6320):78–83. doi:10.1126/science.aah4199
   PubMed Web of Science ®Google Scholar
• Kim J, Jin H, Zhao JC, et al. FOXA1 inhibits prostate cancer neuroendocrine differentiation. Oncogene. 2017;36(28):4072–4080. doi:10.1038/onc.2017.50
   PubMed Web of Science ®Google Scholar
• Tapping CR, Crew J, Proteroe A, Boardman P. Prostatic artery embolization (PAE) for prostatic origin bleeding in the context of prostate malignancy. Acta Radiol Open. 2019;8(6):2058460119846061. doi:10.1177/2058460119846061
   Web of Science ®Google Scholar
• Chen JW, Shin JH, Tsao TF, et al. Prostatic arterial embolization for control of hematuria in patients with advanced prostate cancer. J Vasc Interv Radiol. 2017;28(2):295–301. doi:10.1016/j.jvir.2016.10.010
   PubMed Web of Science ®Google Scholar
• Williams SG, Aw Yeang HX, Mitchell C, et al. Immune molecular profiling of a multiresistant primary prostate cancer with a neuroendocrine-like phenotype: a case report. BMC Urol. 2020;20(1):171. doi:10.1186/s12894-020-00738-8
   PubMed Web of Science ®Google Scholar
• Parikh N, Keshishian E, Manley B, et al. Effectiveness and safety of prostatic artery embolization for the treatment of lower urinary tract symptoms from benign prostatic hyperplasia in men with concurrent localized prostate cancer. J Vasc Interv Radiol. 2021;32(7):1053–1061. doi:10.1016/j.jvir.2021.03.534
   PubMed Web of Science ®Google Scholar
• Conteduca V, Oromendia C, Eng KW, et al. Clinical features of neuroendocrine prostate cancer. Eur J Cancer. 2019;121:7–18. doi:10.1016/j.ejca.2019.08.011
   PubMed Web of Science ®Google Scholar
• Oudard S, Latorzeff I, Caty A, et al. Effect of adding docetaxel to androgen-deprivation therapy in patients with high-risk prostate cancer with rising prostate-specific antigen levels after primary local therapy: a randomized clinical trial. JAMA Oncol. 2019;5(5):623–632. doi:10.1001/jamaoncol.2018.6607
   PubMed Web of Science ®Google Scholar
• Cameron MG, Kersten C, Vistad I, et al. Palliative pelvic radiotherapy for symptomatic incurable prostate cancer - a prospective multicenter study. Radiother Oncol. 2015;115(3):314–320. doi:10.1016/j.radonc.2015.05.021
   PubMed Web of Science ®Google Scholar